PharmaMar is a leading oncology biopharmaceutical company dedicated to advancing cancer treatment through the discovery and development of innovative marine-based drugs. The company’s vision is to provide new drugs from untapped marine sources that respond to society’s need for new, more potent cancer therapies to improve patients’ lives. PharmaMar is the only company that has implemented a program focused on the discovery and development of drugs based on agents of marine origin.
Sylentis S.A. is a R&D company owned 100% by the Zeltia Group. Its goal is to discover and develop new therapeutic approaches based on RNA interference (RNAi) technology. Sylentis investigates new therapies both for diseases with existing treatments which could be improved and diseases for which no treatment exists.
ASEBIO is the Spanish Association of Biotechnology Companies.
ASEBIO brings together companies, associations, foundations, universities, research and technology centers that carry out activities directly or indirectly related to biotechnology in Spain.